Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Multiple Sclerosis

• Safety of Bryostatin in Patients With MS
• Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
• Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
• Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
• Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
• A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
• Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
• Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
• Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants
• A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
• Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
• Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
• Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
• Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy
• Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
• Ketamine for MS Fatigue
• Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
• Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
• Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
• Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis
• First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug;LPX-TI641
• Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
• Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
• AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis
• Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis
• A Study of Imaging in Demyelinating Diseases
• A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
• Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.
• RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
• Dalfampridine in Egyptian Patients With Multiple Sclerosis
• A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis
• A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
• A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
• Vancomycin Study in Multiple Sclerosis (MS)
• A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
• A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
• Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis
• Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
• Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women
• A Phase I Study of LP-168 in Healthy Volunteers
• AttackMS - Treatment of People With Inflammatory Demyelination Suggestive of MS, or Definite MS, at First Presentation
• Study of IMCY-0141 in Recent Onset of Multiple Sclerosis
• An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis
• Ketamine for Multiple Sclerosis Fatigue
• Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
• Novel Imaging Markers in SPMS
• Metformin Treatment in Progressive Multiple Sclerosis
• Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
• Drug Repurposing for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
• B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
• Famciclovir in Multiple Sclerosis
• Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
• Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
• A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In
• LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB
• A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis
• Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
• Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects
• A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
• Natalizumab and Chronic Inflammation
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis
• Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants
• CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Thera
• A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis
• Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
• A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
• Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
• Cannabis as a Complementary Treatment in Multiple Sclerosis
• A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
• Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
• A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
• Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis
• A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
• PET Imaging of Cyclooxygenase-2 in Multiple Sclerosis
• Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
• A Long-term Extension of Study GNC-401
• Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
• Hydroxychloroquine and Indapamide in SPMS
• COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
• A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
• A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
• A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
• Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
• Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants
• Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis
• Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial
• PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers
• Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
• Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
• Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
• Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
• Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis
• A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
• Prevention of Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
• Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
• Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis
• Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
• Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
• Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
• Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
• Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
• Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis
• Histaminergic Basis of Fatigue in Multiple Sclerosis
• Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
• Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
• Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers
• A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
• Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
• ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
• Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
• Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
• A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
• Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis
• Home Based Infusions for Ocrelizumab
• Novel Assessment of Synaptic Density in Progressive MS
• A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
• Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
• Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
• Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis
• Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS)
• A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS)
• Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
• HFP (High-Fiber Supplement) in MS (Multiple Sclerosis)
• Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
• A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
• A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
• A Phase 1 Single and Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 in Healthy Volunteers and Multiple Sclerosis Subjects
• 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
• A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
• Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
• Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
• Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
• Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
• Entire-body PET Scans for Multiple Sclerosis
• Effects of Ocrevus in Relapsing Multiple Sclerosis
• Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.
• Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
• Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
• Minocycline in MS: Confirmation of Benefit
• MitoQ for Fatigue in Multiple Sclerosis (MS)
• Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
• Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).
• To Study the Pathophysiological Features of Multiple Sclerosis
• Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
• Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
• Phase II Clinical Trial of OCH-NCNP1
• Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
• Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis
• Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
• Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
• Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects
• Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
• Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
• Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis
• A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis
• Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
• A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
• Effects of Cladribine Tablets on the PK of Microgynon®
• Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
• A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
• Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis
• Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
• A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
• Study of Evobrutinib in Participants With RMS
• Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
• Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
• Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
• Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
• Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
• 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.
• Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
• RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS
• A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
• Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
• Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
• Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19
• TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
• Simvastatin in Secondary Progressive Multiple Sclerosis
• Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis
• Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)
• Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients
• Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
• To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis
• Short-term B-cell Depletion in Relapsing Multiple Sclerosis
• Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target
• Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique
• MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
• Aspirin for Exercise in Multiple Sclerosis (ASPIRE)
• Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
• Pharmacogenetic Study in Patients With Relapsing Forms of Multiple Sclerosis Who Developed ITP After Receiving Lemtrada
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
• Vaginal Estriol in Multiple Sclerosis
• Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
• BX-1 in Spasticity Due to Multiple Sclerosis
• Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses
• Effects of Cladribine Tablets on the PK of Microgynon®
• A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
• A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
• Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients
• Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV N
• Imatinib for Multiple Sclerosis (MS) Relapses
• Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
• Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
• Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.
• Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue
• A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
• This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
• Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis
• A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
• Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers
• A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
• A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
• Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis
• Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
• Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
• A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
• Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
• Ketamine for Treatment of MS Fatigue
• Melatonin in Patients With Multiple Sclerosis (MS).
• Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
• RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS
• Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
• Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
• A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
• Multiple Sclerosis-Simvastatin Trial 2
• A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)
• Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis
• Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
• Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
• Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
• Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
• Maximizing Outcome of Multiple Sclerosis Transplantation
• A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
• Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
• A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
• Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
• A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS
• A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
• A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
• Neural Stem Cell Transplantation in Multiple Sclerosis Patients
• Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach
• A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
• Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab
• Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
• A Phase 1 Study of ARN-6039
• Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
• Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis
• Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
• Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients
• Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
• The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis
• MitoQ for Fatigue in Multiple Sclerosis
• Lipoic Acid for Progressive Multiple Sclerosis (MS)
• The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients
• Central Pain Study for ABX-1431
• Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
• Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
• Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)
• Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome
• Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis
• A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
• Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
• A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
• Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients
• Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
• Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
• Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis
• Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
• pH Imaging in Multiple Sclerosis
• Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses
• Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms
• Testosterone for Fatigue in Men With MS
• Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
• Safety of Switching From Rituximab to Ocrelizumab in MS Patients
• A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
• A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
• Study of Utilization Patterns of Dimethyl Fumarate in Germany
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
• Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
• MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)
• Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
• National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Init
• Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
• Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
• Hydroxychloroquine in Primary Progressive Multiple Sclerosis
• Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
• Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
• Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate
• Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
• To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS
• Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.
• Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
• Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®
• Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
• A Study of Oxidative Pathways in MS Fatigue
• Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
• Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
• Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
• Methylprednisolone During the Switch Between Natalizumab and Fingolimod
• Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
• Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
• EPID Multiple Sclerosis Pregnancy Study
• RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
• Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
• Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
• Impact of Tecfidera on Gut Microbiota
• Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
• Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
• A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
• Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
• TMP001 in Relapsing-remitting Multiple Sclerosis
• Tecfidera Diffusion Tensor Imaging
• Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
• Clinical Disease Activity With Long Term Natalizumab Treatment
• Adderall XR and Cognitive Impairment in MS
• Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
• Quality Improvement and Practice Based Research in Neurology Using the EMR
• Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
• Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
• Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
• Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
• Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease
• Tecfidera and MRI for Brain Energy in MS
• Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study
• This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
• Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
• Treating Anorectal Dysfunction in MS
• [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis
• A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
• A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period
• Plegridy Satisfaction Study in Participants
• A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
• Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
• A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
• Effect of Fingolimod on Neurodegeneration
• Brimonidine Tartrate for the Treatment of Injection Related Erythema
• Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
• Intrathecal Rituximab in Progressive Multiple Sclerosis
• A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
• Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis
• Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)
• Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
• Single-Dose Study of a New Formulation of BIIB061
• Tecfidera Lymphocyte Chart Review
• Phase I BP Interferon (IFN) Beta-004
• Phase I BP Interferon (IFN) Beta-001
• In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging
• Open-label Study of Liothyronine in MS
• Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
• Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
• Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)
• Teriflunomide Observational Effectiveness Study
• Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
• Baseline Cortical Haemodynamics in MS
• Comparison Study of PF530 and Betaferon in Healthy Subjects
• Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
• Tecfidera and the Gut Microbiota
• Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
• Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
• The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects
• Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
• Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
• BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
• Tecfidera Slow-Titration Study
• Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
• Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
• Oral Guanabenz for Multiple Sclerosis
• Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
• Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
• Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
• Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
• MEsenchymal StEm Cells for Multiple Sclerosis
• An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
• Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
• Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab
• Fingolimod Effect on Cytokine and Chemokine Levels
• Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
• Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
• Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
• Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
• Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
• A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis
• ACTH for Fatigue in Multiple Sclerosis Patients
• Comparative Oral Bioavailability Study of MT-1303
• Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)
• Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
• Imaging of Intracerebral Inflammation in MS
• Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis
• Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
• Mass Balance Study of MT-1303
• Effects of Acthar on Recovery From Cognitive Relapses in MS
• Testing the Effects of Methylphenidate on Multiple Sclerosis
• A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
• A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
• Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)
• Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis
• Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
• Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
• Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS
• Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
• Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
• Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
• A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
• BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
• Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
• Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
• Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
• Plegridy Observational Program
• Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
• Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
• Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
• Effect of MD1003 in Spinal Progressive Multiple Sclerosis
• Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
• Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
• Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS
• Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation
• Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
• A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
• Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
• A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
• Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
• A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
• Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
• Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients
• Resistance Training and Amino Pyridine in Multiple Sclerosis
• Natalizumab Subcutaneous Immunogenicity and Safety Study
• Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya
• Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
• Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
• Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
• Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
• BAY86-5046 (Betaseron), Non Interventional Studies
• RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
• Protective Role of Oxcarbazepine in Multiple Sclerosis
• Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
• Vitamin D3 and the Stress-axis in MS
• Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
• Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
• Safety and Tolerability of Quetiapine in Multiple Sclerosis
• Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis
• An Observational Post-Marketing Safety Registry of Sativex®
• A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
• Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
• Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
• Dimethyl Fumarate (DMF) Observational Study
• A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers
• Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
• Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
• A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
• Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis
• Effects of Dalfampridine on Cognition in Multiple Sclerosis
• Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse
• Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
• A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
• High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
• ATX-MS-1467 in Multiple Sclerosis
• Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV
• A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
• ACTH in Progressive Forms of MS
• Safety and Efficacy of Fingolimod in MS Patients in China
• Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
• A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
• A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
• Biogen Multiple Sclerosis Pregnancy Exposure Registry
• MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
• Comprehensive Analysis of Relapse in Multiple Sclerosis
• Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
• Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses
• Methylphenidate to Improve Balance and Walking in MS
• Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
• Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
• Extension Study of MT-1303
• Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
• Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
• Safety and Tolerability of Glatiramer Acetate
• Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
• Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
• Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
• Avonex®: Safety, Blood Levels and Effects
• Idebenone for Primary Progressive Multiple Sclerosis
• One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
• An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
• A Trial of Neuroprotection With ACTH in Acute Optic Neuritis
• Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications
• Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome
• Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.
• A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
• An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
• GSK239512 DDI Study
• Amiloride Clinical Trial In Optic Neuritis
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
• Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
• Vitamine D in Multiple Sclerosis
• Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
• Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
• Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon
• Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
• Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
• Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis
• Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
• Dose-finding Study of MT-1303
• Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).
• Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis
• Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
• Effect of Melatonin on Multiple Sclerosis Related Fatigue
• Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
• Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
• Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
• Ginseng in Treatment of Fatigue in Multiple Sclerosis
• Alternative Treatment Paradigm for Natalizumab Trial
• The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
• Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis
• Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
• High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
• Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?
• Adderall XR and Processing Speed in Multiple Sclerosis (MS)
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
• FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra
• Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis
• Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
• MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
• Assessing Tolerability of Avonex Intramuscular Injections
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
• Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
• Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination
• Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
• ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
• Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis
• An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
• An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
• A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
• Stem Cells in Rapidly Evolving Active Multiple Sclerosis
• A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
• A Study of the Long-term Safety of Sativex Use
• A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis
• Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
• Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
• A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
• Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.
• NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
• Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
• STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
• An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
• A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
• Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis
• Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
• Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
• Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
• Fampridine Pregnancy Exposure Registry
• Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients
• Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a
• Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers
• Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
• Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
• Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
• Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
• Vitamin D Supplementation in Multiple Sclerosis
• Efficacy and Safety of GTR in Comparison to Copaxone®
• Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
• Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
• An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
• A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
• Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
• An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
• Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
• The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
• Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate
• Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II
• Neuroprotection With Phenytoin in Optic Neuritis
• Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis
• Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)
• Dalfampridine for Imbalance in Multiple Sclerosis
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
• Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)
• China Betaferon Adherence, Coping and Nurse Support Study
• Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
• Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
• Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
• A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
• Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)
• Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
• A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
• Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.
• NOGO-A in Multiple Sclerosis FTIH
• Fingolimod -Response According to Coping - Evaluation
• Impact of Vitamin A on Multiple Sclerosis (MS)
• Healthy Volunteer Study Using 3 Different Formulations of Firategrast
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
• Betaferon® Regulatory Post-Marketing Surveillance
• Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
• Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
• A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability
• Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
• Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
• GSK2018682 FTIH in Healthy Volunteers
• Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
• Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
• A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis
• Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)
• Ampyra for Optic Neuritis in Multiple Sclerosis
• Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
• Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
• Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients
• Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
• Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
• Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis
• Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
• A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
• Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
• Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
• Advanced MRI Measures of Repair in Alemtuzumab Treated Patients
• Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis
• The Gilenya Pregnancy Registry
• Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
• Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
• Melatonin in Relapsing-Remitting Multiple Sclerosis Patients
• Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
• A Pilot Study of Lithium in Progressive Multiple Sclerosis
• Vitamin D Pilot Study in Patients With Multiple Sclerosis
• Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
• Safety Study of BIIB033 in Subjects With Multiple Sclerosis
• Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
• Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
• Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.
• BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program
• AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
• Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
• Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
• Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
• Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
• Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
• Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
• A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
• Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
• Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis
• Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
• REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients
• Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
• Zoledronic Acid in MS-patients With Osteoporosis
• Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis
• BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
• Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis
• A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
• The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis
• Natalizumab De-escalation With Interferon Beta-1b
• An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
• An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
• A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
• A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
• An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
• Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
• Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
• A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
• Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b
• Hydroxyurea in Primary Progressive Multiple Sclerosis
• Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
• Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
• Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
• A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
• Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
• Natalizumab Treatment of Progressive Multiple Sclerosis
• Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period
• Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
• Study on Cognitive Disorders of Multiple Sclerosis
• Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis
• Neuroprotection and Repair in Optic Neuritis
• QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
• Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
• Treatment Interruption of Natalizumab
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
• JC-Virus (JCV) Antibody Program
• A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
• POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
• Pulse ACTH vs. MP for MS
• A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
• Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
• A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
• Effects of Vaporized Marijuana on Neuropathic Pain
• Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
• Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers
• Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
• Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis
• The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor
• Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
• Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
• The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections
• A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
• Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)
• Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses
• Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)
• Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
• Escitalopram (Lexapro) for Depression MS or ALS
• Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
• Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis
• Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
• Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
• Safety of New Formulation of Glatiramer Acetate
• Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b
• Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment
• High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
• Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
• Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
• Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
• Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
• The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
• Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
• Open-Label Safety Extension Study of Avonex
• A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
• Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
• Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction
• A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
• Immunogenicity and Safety Study of Serum-Free Avonex
• Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
• Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
• Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
• BEYOND Pilot Study
• A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
• A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Physical Activity and Fatigue in Early Multiple Sclerosis (MS)
• Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
• Physical Disability in Patients Treated With Betaferon
• A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis
• A Study for Patients With Multiple Sclerosis
• A Study for Patients With Relapsing Remitting Multiple Sclerosis
• A Study for Patients With Secondary Progressive Multiple Sclerosis
• Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis
• Atacicept in Multiple Sclerosis Extension Study, Phase II
• Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
• Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis
• A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
• Safety of Polyphenon E in Multiple Sclerosis Pilot Study
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
• Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
• Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
• Therapy Optimization in Multiple Sclerosis (MS)
• Characteristic Study on Chinese Patients With Multiple Sclerosis
• A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
• Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
• Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
• Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
• Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
• Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus
• Sunphenon in Progressive Forms of Multiple Sclerosis
• Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
• Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
• Rehabilitation Study in MS Patients
• Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
• Chronotherapy in Acute Multiple Sclerosis (MS) Attack
• Duloxetine for Multiple Sclerosis Pain
• American Ginseng Treatment for Multiple Sclerosis Related Fatigue
• Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse
• An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
• An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
• A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
• 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
• This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
• CDP323 Biomarker Study
• Oral Cladribine in Early Multiple Sclerosis (MS)
• Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases
• A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.
• Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
• Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)
• Cannabis for Spasticity in Multiple Sclerosis
• A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
• A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
• A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
• A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis
• Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment
• An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
• Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo
• Minocycline in Clinically Isolated Syndromes (CIS)
• Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
• Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
• Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis
• A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
• CLARITY Extension Study
• Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
• Memantine Therapy for Multiple Sclerosis
• Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS
• Memantine for Spasticity in MS Patients
• Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
• Flupirtine as Oral Treatment in Multiple Sclerosis
• Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
• Transition to Rebif New Formulation
• Combination Therapy Using Cellcept and Rebif in RRMS
• 12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
• Atorvastatin in Relapsing-Remitting Multiple Sclerosis
• Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects
• BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
• Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
• Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)
• FolateScan in Autoimmune Disease
• How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
• Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
• Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
• MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study
• Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients
• BENEFIT Extension Study
• Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)
• Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
• Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis
• A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
• Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
• Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
• Neuroprotection With Riluzole Patients With Early Multiple Sclerosis
• A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone
• Tysabri Observational Program
• Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
• Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
• Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
• Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
• Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis
• Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis
• IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
• Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
• Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
• Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis
• Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
• Optimizing IFN Beta - 1B Dose
• Rebif New Formulation (RNF) Quality of Life (QOL) Study
• Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
• Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
• Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
• Aspirin for Treatment of Multiple Sclerosis-Related Fatigue
• One Year Extension Study To Protocol C2/5/TZ:MS-05
• Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
• Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
• BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
• A Study to Test the Use of Duloxetine for Pain in MS
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
• A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
• A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
• A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
• Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis
• RNF and Betaseron® Tolerability Study
• A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
• Levetiracetam in Central Pain in Multiple Sclerosis(MS)
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
• Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks
• Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis
• Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
• Testosterone Treatment for Multiple Sclerosis
• REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
• An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
• Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
• fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
• Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
• Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
• BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
• Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis
• Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis
• Omega-3 Fatty Acid Treatment in Multiple Sclerosis
• Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
• A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
• Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis
• Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
• Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
• Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
• Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
• Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
• Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
• A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
• Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
• Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
• Combination Therapy of Betaseron-Prograf in Multiple Sclerosis
• Natalizumab (Tysabri) Re-Initiation of Dosing
• Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
• A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
• Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
• High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
• Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients
• Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis
• Open-Label Natalizumab Safety Extension Study
• Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
• Interferon ß-1b Treatment by Cyclical Administration
• FOCUS Fatigue Outcome in Copaxone USers
• Simvastatin Treatment of Patients With Acute Optic Neuritis
• Cannabis for Spasticity in Multiple Sclerosis
• A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
• Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis
• Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
• A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
• Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability
• Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
• A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.
• A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
• A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
• Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
• Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
• Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
• Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis
• Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
• Fatigue Treatment Using Provigil
• Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
• Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
• A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
• A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
• Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
• Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS
• A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
• An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
• Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
• Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
• Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
• A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
• Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
• Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
• Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
• A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
• Use of Cannabinoids in Patients With Multiple Sclerosis
• Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
• Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis
• Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis
• BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
• Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
• Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
• Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
• Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
• Efficacy and Safety of BG00012 in MS
• Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients
• The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis
• Study Evaluating Mitoxantrone in Multiple Sclerosis
• EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis
• Modafinil in Multiple Sclerosis
• A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis
• EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis
• Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
• Study of Oral Fampridine-SR in Multiple Sclerosis
• POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis
• Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis
• AVONEX® Combination Trial - "ACT"
• Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
• A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.
• Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects
• BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
• Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
• Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
• A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
• Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
• A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
• Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
• Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
• Safety of RG2077 in Patients With Multiple Sclerosis
• Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
• Treatment of Multiple Sclerosis Using Over the Counter Inosine
• Improving Memory in Patients With Multiple Sclerosis
• Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
• Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
• Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe
• Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis
• High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis
• Treatment of Multiple Sclerosis With Copaxone and Albuterol
• Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
• Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
• A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
• Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
• Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
• Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis
• Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis
• Rolipram to Treat Multiple Sclerosis
• Natural Antioxidants in the Treatment of Multiple Sclerosis
• Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis
• A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis
• Zenapax to Treat Multiple Sclerosis
• Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)
• A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
• Longitudinal Optic Neuritis Study (LONS)
• Optic Neuritis Treatment Trial (ONTT)